What is the address of Pharmaxx?

The registered office of Pharmaxx is located at Wingensestraat 16, 8020 Oostkamp.

Is Pharmaxx still active?

Yes. According to the CBE (29 October 2026) Pharmaxx is active, legal situation “Normale toestand”, started on 22 April 2022.

Is Pharmaxx registered on Peppol?

Yes, Pharmaxx is registered on the Peppol network with ID 0208:0785318829.

What is the enterprise number of Pharmaxx?

The enterprise number of Pharmaxx is BE0785318829.

When was Pharmaxx founded?

Pharmaxx was founded on 22 April 2022.

Who are the directors of Pharmaxx?

According to the 2025 annual accounts, the directors of Pharmaxx are: Delphine Duran, Emmanuel Van Poucke.

Is Pharmaxx a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 22 April 2022; 2 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Pharmaxx make in 2025?

Pharmaxx posted a profit after taxes of € 14,435 in financial year 2025.

What is the revenue of Pharmaxx?

As a small company, Pharmaxx is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 19,794.

Pharmaxx (Private Limited) - Oostkamp - BE0785318829

Dossier Pharmaxx, printed on 29 October 2026 from databakkes.be/en/0785318829/pharmaxx. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Pharmaxx from Oostkamp, company number BE0785318829, closed financial year 2025 with a result of € 14,435 after tax. For that financial year Pharmaxx recorded a gross margin of € 19,794 and equity of € 54,437. Compared with financial year 2024, the result moved from € 30,001 to € 14,435. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on November 30, 2025.

What it is worth Growing

€ 54,437

▲ 36% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 14,435

▼ 52% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 4,873

▼ 67% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 44,437.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 28,157

▲ 40% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 6,943

▼ 7% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2024	2025	Change 2024 → 2025
Gross margin	€ 39,001 Gross margin 2024: € 39,001 First fiscal year in the series	€ 19,794 Gross margin 2025: € 19,794 ▼ 49% vs 2024 (€ 39,001) Unfavourable step	▼ 49%
Profit after taxes	€ 30,001 Profit after taxes 2024: € 30,001 First fiscal year in the series	€ 14,435 Profit after taxes 2025: € 14,435 ▼ 52% vs 2024 (€ 30,001) Unfavourable step	▼ 52%
Equity	€ 40,001 Equity 2024: € 40,001 First fiscal year in the series	€ 54,437 Equity 2025: € 54,437 ▲ 36% vs 2024 (€ 40,001) Favourable step	▲ 36%
Total debts	€ 37,224 Total debts 2024: € 37,224 First fiscal year in the series	€ 59,364 Total debts 2025: € 59,364 ▲ 59% vs 2024 (€ 37,224) Unfavourable step	▲ 59%
Cash	€ 14,829 Cash 2024: € 14,829 First fiscal year in the series	€ 4,873 Cash 2025: € 4,873 ▼ 67% vs 2024 (€ 14,829) Unfavourable step	▼ 67%
Retained profit	€ 30,001 Retained profit 2024: € 30,001 First fiscal year in the series	€ 44,437 Retained profit 2025: € 44,437 ▲ 48% vs 2024 (€ 30,001) Favourable step	▲ 48%
Balance sheet total	€ 77,225 Balance sheet total 2024: € 77,225 First fiscal year in the series	€ 113,801 Balance sheet total 2025: € 113,801 ▲ 47% vs 2024 (€ 77,225) Unchanged	▲ 47%

Key figures of Pharmaxx, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.

What happened to Pharmaxx?

What happened at Pharmaxx in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Nov 30, 2025 New annual accounts for financial year 2025: profit of € 14,435 (▼ 52% vs 2024). filed late Source: NBB ↗
Apr 22, 2022 New establishment in Oostkamp. KBO
2022 Delphine Duran became a director. NBB
2022 Emmanuel Van Poucke became a director. NBB
Apr 22, 2022 Start of the company according to the CBE. KBO

In short

From € 30,001 profit in 2024 to € 14,435 profit in 2025.

Paid € 11,291 in corporate taxes since 2024.

Best year ever: 2024, with € 30,001 profit.

Original PDFs at the National Bank ↗

Management

Delphine Duran Emmanuel Van Poucke

AUTOMOTIVE GROUP

N & J INVEST

Pharmaxx

Behind Pharmaxx are Delphine Duran and Emmanuel Van Poucke. Delphine Duran is also behind AUTOMOTIVE GROUP and N & J INVEST.

Directors

According to the 2025 annual accounts

Delphine Duran

Director

Also active at: AUTOMOTIVE GROUP, N & J INVEST

since 2022

Emmanuel Van Poucke

Director

since 2022

Establishments

Establishment units

Physical locations of this company

Registered office

Wingensestraat 16

8020 Oostkamp

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

QARDEA

€ 357,789 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0785.318.829
VAT number: BE 0785.318.829
Registered office: Wingensestraat 16, 8020 Oostkamp
Names & denominations: Pharmaxx
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 22 April 2022
Peppol: Active · Active since 31 Oct 2023

View on CBE Public ↗ Annual accounts (NBB) ↗